Jyong Biotech (NASDAQ:MENS) Stock Price Up 2.7% – Time to Buy?

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price traded up 2.7% during mid-day trading on Thursday . The stock traded as high as $2.33 and last traded at $2.30. Approximately 14,428 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 37,089 shares. The stock had previously closed at $2.24.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech presently has a consensus rating of “Sell”.

Jyong Biotech Stock Performance

The stock’s 50 day simple moving average is $2.15 and its 200-day simple moving average is $2.12.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MENS. Man Group plc purchased a new stake in Jyong Biotech in the fourth quarter valued at approximately $56,000. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech in the 3rd quarter valued at $67,000. Millennium Management LLC lifted its position in Jyong Biotech by 209.4% during the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after purchasing an additional 27,245 shares during the period. Geode Capital Management LLC grew its position in Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Jyong Biotech in the 4th quarter valued at about $275,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.